You are here

Article metrics

Article menu
Basic tumor immunology
Original research
Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity

 

Online download statistics by month:

Online download statistics by month: November 2022 to February 2026

AbstractFullPdf
Nov 2022727318
Dec 2022659667250
Jan 2023440442127
Feb 2023329330120
Mar 2023309311103
Apr 2023291292129
May 202325826372
Jun 202324524774
Jul 202327627774
Aug 202320921456
Sep 202318618974
Oct 202325425476
Nov 2023339343113
Dec 2023240245109
Jan 2024184187151
Feb 202417417672
Mar 2024271271115
Apr 202421922088
May 202420720775
Jun 202422722978
Jul 202429229553
Aug 2024270267110
Sep 2024425428482
Oct 2024361361176
Nov 2024313314159
Dec 2024338341107
Jan 202537437491
Feb 2025502502138
Mar 2025412413197
Apr 2025365365132
May 2025354354112
Jun 202521922190
Jul 2025110
Nov 2025110
Feb 2026110
Total961796753821